INmune Bio (INMB) Plunges 27.68% Amid Equity Offering

INmune Bio (INMB) experienced a significant decline, dropping 15.13% over two consecutive days, with a total decrease of 27.68% in the past two days. The share price reached its highest level since May 2024 today, with an intraday gain of 85.35%. However, it also fell to its lowest level since January 2025, with an intraday decline of 20.22%.

The impact of INMB stock price reaching a new high on future price movements is likely to be positive, based on the company's strong recent performance and market enthusiasm for its Alzheimer's disease trial data. Here's an analysis of the stock price performance over the next 1 week, 1 month, and 3 months after reaching a new high:

Next 1 Week: The stock is likely to experience continued upward momentum in the immediate aftermath of reaching a new high. This is due to the excitement surrounding the upcoming Alzheimer's trial data release and the overall positive sentiment surrounding the company. The stock may experience some volatility due to investors booking profits or adjusting their positions ahead of the data release. Expected Movement: Moderate increase, with potential for short-term fluctuations.

Next 1 Month: After the initial excitement wears off, the stock's performance will likely be influenced by the outcome of the Alzheimer's trial data release. If the data is positive, the stock could see a significant boost in confidence from investors, leading to further price appreciation. Conversely, if the data is neutral or negative, the stock may experience a correction. Expected Movement: Positive if the trial data is favorable, otherwise, a potential pullback.

Next 3 Months: The stock's performance will be influenced by the broader market conditions, the company's pipeline progress, and the impact of the equity offering. Assuming the company continues to make progress in its pipeline and maintains positive relationships with investors, the stock could see steady growth. However, the equity offering could lead to dilution and may weigh on the stock price in the short term. Expected Movement: Steady growth if pipeline progresses positively, potentially impacted by dilution from equity offering.

It's important to note that these predictions are based on the current market conditions and the company's recent performance. Investors should also consider the risks associated with the biotech industry, including the potential for negative clinical trial results and regulatory uncertainties.

On June 27, 2025, INmune Bio announced a $19 million registered direct offering priced at-the-market under Nasdaq rules. This capital raise from healthcare-focused investors is intended to advance the company's inflammation and immunology pipeline. The announcement of this equity offering resulted in a notable drop in INMB's stock price. The company plans to announce top line results from the Phase 2 MINDFuL trial in early Alzheimer's Disease on June 30, 2025, which could further impact stock prices depending on the trial outcomes.

INmune Bio's recent equity offering and upcoming trial results have created a mix of uncertainty and anticipation among investors. The capital raise is seen as a strategic move to support the company's pipeline, but the immediate market reaction was negative, reflecting investor concerns about dilution and the potential impact on earnings per share. The upcoming Phase 2 MINDFuL trial results for early Alzheimer's Disease are highly anticipated, as a positive outcome could significantly boost investor confidence and drive the stock price higher. Conversely, a negative result could lead to further declines. Investors are closely monitoring these developments, as they could shape the company's trajectory in the coming months.